Destiny Pharma plc
("Destiny Pharma" or "the Company")
Cardiac surgery patients treated with XF-73 Nasal gel require significantly fewer post-surgical antibiotics
Further data from Phase 2b study to be presented at ID Week, a leading US infectious disease conference
The title of the presentation is, 'Impact of Exeporfinium Chloride (XF-73) Nasal Gel on the Use of Post-Operative Anti-staphylococcal Antibiotics in Cardiovascular Surgery Patients: Results from a Randomised, Placebo-Controlled Phase 2 Study.'
Previously, the Company reported on achieving the primary endpoint for XF-73 Nasal gel, i.e. >99% reduction in nasal S. aureus compared to placebo one hour before open heart surgery, (p < 0.0001), Mangino et al. 20231.
Further planned data analysis of a secondary endpoint within the clinical trial investigated the use by physicians of post-surgical systemic antibiotics prescribed >48 hours after surgery. Significantly fewer patients in the XF-73 treatment arm received post-operative anti-staphylococcal antibiotics: 46.5% (20 of a total population of 43), compared to 70% (28 of a total population of 40) in the placebo group, p=0.045, which suggests that antibiotics may have been prescribed as an early intervention in more patients in the placebo arm.
The observed reduction of the use of post-operative antibiotics in the XF-73 arm is consistent with the principles of good antimicrobial stewardship which are crucial for managing and preventing infections more effectively and for maintaining the efficacy of antibiotics, reducing healthcare complications, and improving patient safety.
Additional advantages of the XF-73 Nasal gel include the short, 24 hour, pre-surgical dosing regimen, rapidity of S. aureus nasal decolonisation, remote likelihood of resistance emergence, and the duration of effect. These features provide a good fit with clinical practice, potentially enabling infection risk reduction peri-operatively, enhancing flexibility for scheduling surgeries, and augmenting antibiotic stewardship efforts. Phase 3 studies are being planned to evaluate and gain regulatory approval for XF-73.
XF-73 has also demonstrated efficacy against the hospital superbug methicillin-resistant Staphylococcus aureus (MRSA). In studies published last year XF-73 was potent against all 840 MRSA strains collected from infected patients from 33 countries worldwide (Rhys Williams et al. 2023)2 and was shown to be up to 1000 times more efficacious than nasal mupirocin (the most commonly used nasal antibiotic) at treating MRSA in a skin infection model, (Zhang et al. 2023)3.
Dr Debra Barker, Interim Chief Medical Officer of Destiny Pharma, said: "The data to be presented at ID Week highlights the ability of XF-73 Nasal gel to significantly reduce the need for post-surgical antibiotic use. With antimicrobial resistance continuing to present an existential threat, these data highlight the value that XF-73 Nasal can provide in meeting this challenge while delivering favourable patient outcomes."
References:
1. Mangino JE, Firstenberg MS, Milewski RKC, et al., 2023. Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study. Infection Control & Hospital Epidemiology, 2023;44(7):1171-1173. doi:10.1017/ice.2023.17
2. William Rhys-Williams, Helen Marie Galvin and William Guy Love, 2023. Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates. Frontiers in Cellular and Infection Microbiology, 2023; 13. doi.org/10.3389/fcimb.2023.1264456
3. Zhang, C., Li, J., Lu, R., Wang, S., Fu, Z., & Yao, Z., 2023. Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73), Against Antibiotic-Resistant Bacteria in Mouse Superficial Skin Infection Models. Infection and Drug Resistance, 16, 4867-4879. doi.org/
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.
For further information on the company, please visit www.destinypharma.com.
Forward looking statements
Certain information contained in this announcement, including any information as to the company's strategy, plans or future financial or operating performance, constitutes "forward-looking statements". These forward looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "aims", "plans", "predicts", "may", "will", "seeks" "could" "targets" "assumes" "positioned" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the company's results of operations, financial condition, prospects, growth, strategies and the industries in which the company operates. The Directors of the company believe that the expectations reflected in these statements are reasonable but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the company's control. Forward looking statements are not guarantees of future performance. Even if the company's actual results of operations, financial condition and the development of the industries in which the company operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.